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Abstract
Background: Gefitinib, an oral agent of epidermal growth factor receptor tyrosine kinase inhibitor, has a certain
efficacy against non-small cell lung cancer (NSCLC). Several predictive factors of gefitinib sensitivity have been
well described. However, few studies have investigated the clinical features of gefitinib-responders. In the present
study, we analyzed the response and disease progression of primary and metastatic lesions to gefitinib in
responders and the results of gefitinib readministration following temporary cessation of gefitinib upon
progression of initial gefitinib treatment and other treatments.
Method: We retrospectively evaluated the clinical courses of 27 NSCLC patients who received gefitinib and
achieved either a complete or partial response.
Results: The best-response rate and disease-control rate against the initial chemotherapy for the gefitinib-
responders were 27.3% and 77.3%, respectively. Favorable efficacy was observed in the primary lesion and
metastases to the lung, liver and brain, while there was no obvious effect on bone metastasis. The primary lesion
and intrapulmonary metastasis were the sites of major recurrence. Median progression-free survival was 13.8
months, median duration of gefitinib treatment was 17.0 months and median overall survival was 29.2 months.
Some of the patients who experienced disease progression after responding to gefitinib were again sensitive to
readministration of gefitinib following temporary cessation of gefitinib and other treatments.
Conclusion: Patients may still be expected to have prolonged survival if they once responded to gefitinib and
then underwent various subsequent treatments followed by readministration of gefitinib. These findings might
provide valuable information for the management of gefitinib-responders.
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Background
Although chemotherapy improves survival in advanced
NSCLC patients, it appears to have reached a therapeutic
plateau and novel approaches are urgently required.
Under these circumstances, inhibition of the epidermal
growth factor receptor (EGFR) tyrosine kinase has
emerged as a therapeutic option in patients with NSCLC.
Gefitinib, an oral EGFR tyrosine kinase inhibitor (EGFR-
TKI), is a leading agent in this class of novel therapeutic
agents. It is now clear that there are limited subgroups of
patients who derive particular benefit from this treatment.
Two major phase II trials [1,2], large expanded access pro-
grams across the world [3-6] and other studies [7,8] have
demonstrated a higher objective-response rate and pro-
longed survival in women, never-smokers, patients with
adenocarcinoma, and East-Asian patients. Moreover, a
prospective trial using gefitinib as a first-line therapy for
advanced lung adenocarcinoma patients with never
smoking status was conducted in Korea, with excellent
efficacy confirmed [9].
A molecular approach linked to gefitinib sensitivity has
also been attempted. Mutations [10,11] and amplification
[12] of the EGFR gene, and other molecules such as phos-
phorylated Akt [13] and ErbB-3 expression [14] have been
well described as markers of a better outcome in patients
treated with gefitinib. Furthermore, correlation between
some of these predictors and clinical benefit has been ret-
rospectively confirmed in many reports [15-22]. However,
few reports have examined the clinical courses of gefit-
inib-responders.
In the present study, we investigated the clinical courses of
gefitinib responders, by analyzing the response and dis-
ease progression of primary and metastatic lesions by
gefitinib in responders and the results of gefitinib read-
ministration (resumption of, or rechallenge with, gefit-
inib) following temporary cessation of gefitinib upon
progression of initial gefitinib treatment and other treat-
ments. Our results provide additional information regard-
ing gefitinib use for advanced NSCLC patients.
Methods
Patients and treatment
From August 2002 to March 2004, a total of 122 patients
with histologically or cytologically confirmed advanced
NSCLC received 250 mg/day gefitinib orally at our insti-
tutes (Hokkaido University Hospital, National Hospital
Organization Hokkaido Cancer Center, Sapporo City
General Hospital and Fukushima Medical University Hos-
pital, Japan). We reviewed their medical records and
imaging findings. The histopathological classification was
based on WHO criteria [23]. Treatment was primarily con-
tinued until disease progression (PD), death, intolerable
side effects determined by physicians or withdrawal of
consent. No other systemic chemotherapy was performed
during gefitinib treatment in any of the patients, although
some received radiotherapy for metastasis or pleurodesis
after temporary cessation of gefitinib, followed by
resumption of gefitinib.
The clinical features of the 27 (22.1%) patients who were
defined as having a complete (CR) or partial response
(PR) to gefitinib were retrospectively analyzed. Objective
tumor response was determined in accordance with the
Response Evaluation Criteria in Solid Tumors Group
(RECIST) guidelines [24]. Disease control was categorized
as CR, PR, or stable disease (SD). CR and PR required a
sustained response for 4 weeks or longer, while this was 8
weeks or longer for SD. Most patients who started gefit-
inib were admitted to hospital and underwent weekly
chest X-rays for the initial 4 weeks, and then underwent
monthly chest X-rays and computed tomography (CT)
including target lesions with or without brain magnetic
resonance imaging (MRI) or bone scintigraphy every three
months at the outpatient clinic. Objective tumor response
was confirmed by CT, MRI, and bone scintigraphy. Pro-
gression-free survival (PFS) and overall survival (OS) were
calculated from the date of initiation of gefitinib. Patients
who were not deceased were censored at the date of last
contact with our institutions. The duration of gefitinib
treatment was calculated from the date of initiation of
gefitinib to the date of withdrawal of gefitinib. In the
present study, readministration of gefitinib was divided
into resumption and rechallenge of gefitinib. "Resump-
tion of" or "resuming" gefitinib indicates the restarting of
gefitinib administration within 4 weeks after cessation of
gefitinib and other treatments such as radiotherapy for
metastasis or pleurodesis, but not chemotherapy. "Rechal-
lenge" with gefitinib indicates the restarting of gefitinib
after cessation of gefitinib and cessation of several cycles
of other chemotherapy.
Statistical analysis
PFS and OS probability estimates were based on the Kap-
lan-Meier method. Confidence intervals were calculated
at the 95% level (95% CI). Dr. SPSS software (SPSS, Inc.,
Chicago, IL) was used for the analyses.
Results
Differential response and disease progression of primary 
and metastatic lesions by gefitinib
Of the entire cohort of 122 patients who were treated with
gefitinib, 27 (22.1%) were defined as PR. No patient
achieved CR. Female patients, patients with never-smoked
status and patients with adenocarcinoma showed a higher
response as described previously [7].
Table 1 shows the response of primary and metastatic
lesions to gefitinib in the responders. The primary tumorBMC Cancer 2007, 7:51 http://www.biomedcentral.com/1471-2407/7/51
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shrunk by 46.5 ± 19.4% (mean ± SD) in the 21 assessable
gefitinib-responders. At the start of gefitinib administra-
tion, 12 patients (44.4%) had intrapulmonary metastases,
all of which regressed by gefitinib. The intrapulmonary
metastases in 9 patients were assessed as target lesions and
the percentage of shrinkage of these target lesions was
73.8 ± 30.6%. The response of liver and brain metastases,
and pleural effusion, to gefitinib was also favorable. Bone
metastasis was initially detected in 8 patients (29.6%),
and remained unchanged after gefitinib treatment, as con-
firmed by bone scintigraphy.
The sites of initial disease progression after response to
gefitinib among the 27 responders are summarized in
Table 2. The initial recurrent sites were seen in the primary
lesion in 8 (29.6%) patients, intrapulmonary lesion in 8
(29.6%), bone in 5 (18.5%), central nervous system
(CNS) in 3 (11.1%), and pleural effusion in 6 (22.2%).
Gefitinib readministration following temporary cessation 
of gefitinib upon progression of initial gefitinib treatment 
and other treatments
Table 3 shows the clinical courses of initial gefitinib-
responders upon progression of initial gefitinib treat-
ment. At the time of writing, 3 responders are maintaining
PR and remain on gefitinib. Two patients have ceased
gefitinib during PR at their request, and the other 22
patients have developed PD. Of these 22, 4 continued to
receive gefitinib at their request and regardless of PD and
the availability of other treatments.
Another 4 of the 22 patients with PD underwent various
treatments, except chemotherapy, for new or progressed
lesions and then resumed gefitinib (Table 4). Patient 1
developed a new bone metastasis and increment of malig-
nant pleural effusion regardless of regression of intrapul-
monary tumors. This patient received irradiation for the
bone metastasis, pleurodesis, and then resumed gefitinib.
Patient 2 developed a brain metastasis and thus under-
went whole brain irradiation, after which gefitinib was
resumed because intrathoracic disease remained well con-
trolled. Patient 3 developed a new bone metastasis regard-
less of good control of intrathoracic disease. The patient
underwent irradiation for the bone metastasis and then
resumed gefitinib. Patient 4 who had well-controlled
intrapulmonary tumors, underwent irradiation for brain
and bone metastases, pleurodesis, and then gefitinib
again. Judging from the dates of resumption, all 4 patients
were confirmed as SD. The range of time to re-progression
was from 2.9 months to more than 19.1 months.
Nine of the 22 patients underwent systemic chemother-
apy when reaching PD. Of these 9 patients, 6 chose to
receive gefitinib again after chemotherapy (Table 5). Judg-
ing from the point of rechallenge of gefitinib, one patient
achieved PR, three patients SD, one patient PD and one
Table 1: The response of primary and metastatic lesions to gefitinib in responders
Site No. of patients No. improved No. of patients with target lesion Average tumor shrinkage of target lesion (%, mean ± SD)
Primary lesion 27 27 21 46.5 ± 19.4
Metastatic lesion
Intrapulmonary 12 12 9 73.8 ± 30.6
Liver 4 4 3 47.3 ± 21.6
CNS 4 4 2 65.0 ± 21.2
Bone 8 0
Pleural effusion 6 5
Others 2 2
CNS, central nervous system
Table 2: The sites of initial disease progression after response to gefitinib
Site No. of patients %
Primary lesion 8 29.6
Metastatic lesion
Intrapulmonary 8 29.6
Pleural effusion 6 22.2
Bone 5 18.5
CNS 3 11.1
Others 0 0
CNS, central nervous systemBMC Cancer 2007, 7:51 http://www.biomedcentral.com/1471-2407/7/51
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patient was not evaluative (NE). The range of time to re-
progression from gefitinib rechallenge was 0.6 months to
7.8 months.
In the present cohort of 122 patients, the median follow
up of the 27 initial gefitinib-responders was 23.7 months,
the median PFS,13.8 months (95% CI = 11.4 to 16.2
months); and the median OS, 29.2 months (95% CI =
22.1 to 36.4 months) (Figure 1). The estimated 1-year sur-
vival rate was 85.2%. Because many patients continued to
take gefitinib even after disease progression, the median
duration of gefitinib treatment was 17.0 months (95% CI
= 13.2 to 20.8 months).
Discussion
In the present retrospective study, we analyzed the clinical
courses of gefitinib-responders during and after failure of
the treatment by analyzing the response and disease pro-
gression of primary and metastatic lesions by gefitinib in
responders, and the results of gefitinib readministration
following temporary cessation of gefitinib upon progres-
sion of initial gefitinib treatment and other treatments.
The median PFS and median duration of gefitinib treat-
ment were 13.8 months and 17.0 months, respectively,
revealing an approximately 3.2 month difference between
PFS and the time to cessation of gefitinib. In some
patients, other treatments against pleural effusion, or
against bone or brain metastasis, were successful, while
intrapulmonary or intrathoracic diseases were stable. Phy-
sicians and patients decided together whether to continue,
resume or rechallenge with gefitinib.
One of the most striking results in the present study was
that PR or SD was achieved upon gefitinib rechallenge fol-
lowing systemic chemotherapy in 4 of 6 patients who
responded to the first administration of gefitinib. There
has been only one similar case reported [25]. This phe-
nomenon is difficult to explain. One possibility is that the
passage of time or cytotoxic chemotherapy may have
reduced the number of clones containing modified genes
and proteins that confer resistance to gefitinib. The mech-
anism of this phenomenon may involve a second point-
mutation, resulting in a threonine-to-methionine amino
acid change at position 790 of EGFR (T790M) [26,27],
mutation in the KRAS protein [28], or upregulation of epi-
thelial membrane protein-1 [29]. It would be of great ben-
efit to perform comparative molecular analyses of tissue
specimens before and after gefitinib treatment in respond-
ers.
In the present study, the OS was 29.2 months, which was
much longer than that in three previous retrospective
reports [19,30,31] focusing on patients who had
responded to gefitinib (16 to 20.3 months). Differences in
gender, never-smoked status, presence of adenocarci-
noma, and ethnicity may be responsible in part for the
altered outcome between the responders in the present
study and those in the three previous studies. Moreover,
the strategy of resumption or rechallenge of gefitinib for
gefitinib-responders may also have played a role in the
longer survival observed in the present study.
Hotta et al. [32] noted the importance of achieving SD
with gefitinib, based on their finding that the OS in
Table 4: Clinical course of the gefitinib-responders who achieved PD, underwent various treatments except for chemotherapy, and 
resumed gefitinib
No. Treatment after gefitinib failure Response after gefitinib resumption Time to re-progression (month)
1 RT to bone mets, Pleurodesis, SD 2.9
2 RT to brain mets, SD 8.9
3 RT to bone mets, SD 19.1+
4 RT to bone and brain mets, Pleurodesis, SD 6.5
"Resumption" of gefitinib indicates restarting gefitinib within 4 weeks after temporary cessation of gefitinib. RT, radiotherapy; mets, metastasis; 
Time to re-progression, time to progression from the date of resuming gefitinib; +, still continuing the response at the last date of follow-up
Table 3: Clinical course of gefitinib-responders
Clinical course No. of patient
Maintain PR and still continue 3
Cessation by patient's will during PR 2
Disease progression (PD) 22
Insistence to continue 4
Resumption 4
Rechallenge 6
Cessation of gefitinib by PD and no therapy 8BMC Cancer 2007, 7:51 http://www.biomedcentral.com/1471-2407/7/51
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patients who obtained SD was significantly longer than
that in patients with PD. It is of interest whether resump-
tion of, or rechallenge with, gefitinib after treatment of a
recurrence site contributes to the patients' survival by
achieving PR or maintaining SD for a long time. With
regard to rechallenge, we are performing a prospective
phase II trial of gefitinib rechallenge to gefitinib-respond-
ers following chemotherapy.
Our analysis of the initial sites of disease recurrence in
patients who initially responded to gefitinib revealed a
relatively higher prevalence of intrapulmonary and pri-
mary lesion metastasis at the initial disease recurrence site
than at other organs. Furthermore, although a previous
report [30] noted that CNS metastasis was a frequently
observed disease recurrence site (33%) in gefitinib-
responders, only 3 patients (11.1%) developed CNS
metastasis in the present study. There were more patients
who had pleural effusion or bone metastasis at the initia-
tion of gefitinib in our cohort.
Conclusion
Patients may still be reasonably expected to have pro-
longed survival if they once responded to gefitinib and
then underwent various subsequent treatments followed
by failure of a second round of gefitinib. These findings
provide valuable information for the management of
gefitinib-responders. Further research and clinical trials
Table 5: Clinical course of the gefitinib-responders who achieved PD, underwent chemotherapy, and rechallenged with gefitinib
No. Chemotherapy regimen after failure of 
gefitinib
Best response of the 
chemotherapy
Response of gefitinib 
rechallenge
Time to re-progression 
(month)
5 GEM+VNR PR PR 6.2
6 GEM+VNR PD SD 7.8
7 GEM+DTX SD PD 0.6
8C B D C A + C P T - 1 1   → AMR → S-1 SD SD 1.9+
9 DTX SD SD 4.3+
10 DTX SD NE 0.9+
"Rechallenge" of gefitinib indicates restarting gefitinib after cessation of gefitinib followed by other chemotherapy. GEM, gemcitabine; VNR, 
vinorelbine; DTX, docetaxel; CBDCA, carboplatin; CPT-11, irinotecan; AMR, amrubicin; Time to re-progression, time to progression from the date 
of rechallenging gefitinib; +, still continuing the response at the last date of follow-up
Kaplan-Meier estimates of progression-free survival (PFS, A) and overall survival (OS, B) for gefitinib-responders Figure 1
Kaplan-Meier estimates of progression-free survival (PFS, A) and overall survival (OS, B) for gefitinib-respond-
ers. Median PFS was 13.8 months (95% CI = 11.4 to 16.2 months) and median OS was 29.2 months (95% CI = 22.1 to 36.4 
months). Bars indicate censored cases.
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based on the present findings will be needed to develop
more effective treatment strategies and to improve the
clinical practice of appropriate gefitinib administration in
advanced NSCLC patients.
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